(423) 989-8000     info@upm-inc.com

UPM Leadership Team

John-GregoryServing as Chairman and CEO for Gregory Pharmaceutical Holdings Inc., John M. Gregory is a pioneer in specialty pharmaceuticals. In 2002, John received the Ernst & Young Entrepreneur of the Year award, honored as the winner in the Health Sciences category. After graduating from the University of Maryland with a degree in pharmacy, John and his wife, Joan, moved to Bastian, Virginia, where he opened the town’s first retail pharmacy. Seeing an opportunity to expand, in 1984 John co-founded General Injectables and Vaccines (GIV), a company that supplied injectables and vaccine products directly to physicians’ offices. As president and CEO, John turned GIV into a successful enterprise with 550 employees and annual revenues exceeding $150 million annually. With a small initial investment in their pockets and a lot of debt on their shoulders, John and his brothers purchased a pharmaceutical manufacturing facility in Bristol, Tennessee, in 1993. Under John’s leadership as chairman and CEO from 1993-2001, King Pharmaceuticals grew from a 90-employee family business to an S&P 500 Index company on the New York Stock Exchange with revenues exceeding $1 billion.
James E. Gregory served as the President and Chief Operating Officer of UPM from 2004 to 2007. After retiring in January, 2008, he was reappointed to this position in October, 2009. Gregory previously worked for King Pharmaceuticals from 1995 to 2000 as Executive Vice President and General Manager of King’s Bristol, Tennessee manufacturing facility. He served in various consulting capacities at King from 2000 to 2003 and served on the Board of Directors in 2002 and 2003. Gregory served from 1982 to 1995 as a senior administrator in the court systems of Phoenix, Arizona and Washington, D.C. He was deputy executive officer in charge of business operations of the District of Columbia Court System from 1990 to 1995. Gregory has a B. A. from the University of Maryland and a masters in public administration from American University.
Gary-HollenbeckDr. Hollenbeck has been a member of UPM’s senior management team since its inception in 1997 and he assumed the position of Chief Scientific Officer, January 1, 2006. He serves as a key scientific and technical advisor at UPM and personally directs focused research and development projects in the area of novel drug delivery platforms. Dr. Hollenbeck also currently oversees the technical services, manufacturing, and materials management groups at the Baltimore facility. Prior to assuming the full-time position at UPM, he was most recently Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy. He received his B.S. degree from Albany College of Pharmacy and his Ph.D. in Industrial and Physical Pharmacy from Purdue University. Hollenbeck was Associate Dean for Academic Programs at the UM School of Pharmacy from 1991 to 1996, and was one of the principal architects of the School’s nationally recognized Doctor of Pharmacy program. During that period, he was also co-principal investigator on the UMAB/FDA Collaborative Agreement; a joint education, research and computer database effort aimed at establishing a scientific basis for review of new and amended drug applications. In this capacity, he and his associates received a Special Recognition Award for the SUPAC IR Training Program, from the Center for Drug Evaluation and Research, FDA, PHS, DHHS. Hollenbeck also served as a member of the Advisory Committee on Pharmaceutical Science, Office of Pharmaceutical Science at FDA and in 2003 received a DHHS, FDA Commissioner’s Special Citation for his work with the Center for Veterinary Medicine. Dr. Hollenbeck is a member of the Editorial Advisory Board for Pharmaceutical Technology and continues to serve as Adjunct Professor of Pharmaceutical Sciences at the UM School of Pharmacy.
Dr. Scholtz is responsible for UPM’s Research and Development Division. He also personally manages numerous formulation and development projects. Prior to joining UPM, Dr. Scholtz enjoyed 22 years working in various sophisticated scientific and management positions for Merck & Company. These positions included site automation compliance, worldwide quality assurance, manufacturing division regulatory compliance, and pharmaceutical R&D leadership on large, complex, new product formulation/process development project teams. Dr. Scholtz is the co-author of four patents, numerous publications, and many presentations at professional meetings. He received his B.S. degree in Pharmacy from the University of Pittsburgh, an M.S. in Pharmaceutical Sciences from the same institution and his Ph.D. in Industrial and Physical Pharmacy from Purdue University.
Dr. Spaven oversees early stage Client-UPM project contracting, requests and deliverables. Prior to joining UPM, Dr. Spaven spent ten years with the Medical Products Business at E.I. DuPont de Nemours. Her assignments there included: Process Chemist in R&D, Manager of a cGMP Tablet and Blend production area, and Technical Manager of Specialty Reagents and Industrial Pharmacy Divisions. During this time, Dr. Spaven also participated on the following committees: ISO-9001 certification, Business Resource Planning, Product Development and Commercialization Framework, Consumables Product Approval Committee (CPAC), Medical Products Professional Progression Committee (PPC) and the Technology Advisory Panel. The CPAC reviewed and approved all new and revised products for funding and resourcing; the PPC recommended for approval all senior level technical promotions. The TAP evaluated and approved funding for new research and technology scouting efforts. Dr. Spaven also has contributed her time to programs such as Junior Achievement, Telementoring Science, and Education and Business Alliance; programs all aimed at encouraging young adults in science careers. Dr. Spaven earned her Ph.D. in Pharmaceutical Chemistry from the University of Maryland School of Pharmacy.
Frank Sorce serves as UPM’s Vice President of Business Development. Mr. Sorce has over 25 years experience in sales, marketing, and business development in the pharmaceutical and medical device industry and has a passion for meeting and exceeding client expectations. Mr. Sorce joined UPM in 2007 as Director, Marketing and Northeast Sales, and was appointed Senior Director, Business Development and Marketing in 2015. Mr. Sorce began his career with Merck Sharp & Dohme as a professional representative in Brooklyn NY, and was an initial member of the Astra Merck Group. Thereafter, Mr. Sorce has held senior sales leadership positions of Regional Business Director with Reliant Pharmaceuticals, National Sales Director with InVentiv Health, and Director, National Sales for Songbird Hearing with responsibility for all sales and marketing efforts in North America. Mr. Sorce holds a BS degree in Management Science from Kean University, and an MBA in Marketing from Seton Hall University.
Richard Green serves as UPM’s Vice President of Manufacturing. Mr. Green has most recently served as site operations director for AAIPharma’s Wilmington, NC solid dose facility and their Charleston, SC parenteral facility. He has 10 years’ experience managing solid dose operations for AAIPharma and over 30 years’ experience in manufacturing operations for several well-known pharmaceutical companies. Mr. Green has worked in OTC, brand and generic manufacturing in the development and commercial production of solid dosage products. He also has 3 years’ experience in sterile and liquid manufacture as well. Richard has been involved in bringing nearly 30 drugs to market for a variety of companies/clients from their initial development through commercial launch, including either the transfer or process validation activities as well as dealing with FDA for routine or specific inspections (PAI/Validation). He received his Bachelor of Science Degree from the University of Tennessee.
Dr. Brennan joined Gregory Pharmaceuticals Holdings (GPH) in 2013. During his tenure, he has held key leadership roles in Regulatory Affairs and Quality Assurance For UPM Pharmaceuticals and NFI Consumer Products. Previously, Dr. Brennan was EVP of Regulatory Affairs for Graceway Pharmaceuticals (Bristol TN). Prior to relocating to the lovely state of Tennessee in 2007, Dr. Brennan enjoyed 25 years working in pharmaceutical development roles of increasing responsibility at the Parke-Davis Division of Warner Lambert and Pfizer in analytical chemistry, regulatory affairs and quality assurance. Dr. Brennan was actively involved in the global development and approval of over 14 new commercial products.
Mr. Curtin serves as UPM’s Senior Vice President of Quality Operations. He has 40 years of industry experience in both domestic and international markets related to Quality, Manufacturing, Supply Chain, Pharmaceutical Technology and Engineering. Mr. Curtin has held executive management positions at Parke-Davis/Warner Lambert, King Pharmaceuticals, Graceway Pharmaceuticals, Rockward Pharmaceutical Consultants, Actient Pharmaceuticals and mostly recently Lynwood Pharmaceuticals. He has developed and installed quality systems as well as managed and remediated a consent decree. He has overseen the design, construction and validation of multiple pharmaceutical facilities and utility systems covering all dosage forms both in the US and OUS. While at Parke Davis/Warner Lambert he held VP positions for Sterile Operations in areas of Quality, Manufacturing and Technical Services. While serving King Pharmaceuticals as Executive Vice President Quality Operations, he was responsible for the Quality Operations of five US based manufacturing sites covering all dosage forms. At Graceway Pharmaceuticals as Executive Vice President Technical Operations , Mr. Curtin was responsible for all Quality, Supply Chain, Manufacturing and Engineering Operations for US, Canada and Mexico. This included oversight of 7 CMO’s producing sterile, solid and semi-solid dosage forms at US and OUS sites. Serving as Executive Vice President Technical Operations for Rockward Pharmaceutical Consulting he advised private equity firms on potential Pharma Acquisitions and transactions. He also served as Vice President of Quality for Actient Pharma and in this role he developed and established quality systems for the company and its products. While at Lynwood Pharma he held position of Executive Vice President, Technical Operations and was responsible quality and manufacturing systems and strategies for implementing the plans for development of multiple ANDA’s for solid and semi solid products. Mr. Curtin has spoken both domestically and internationally on topics of validation and qualification, design of HVAC systems, validation strategy for vaccine products, environmental monitoring and sterilization processes.
Mr. Rutledge serves as UPM’s Vice President of Quality Assurance. He has 38 years of industry experience related to Bench Chemistry, Quality Control Management, Quality Assurance Management, Pharmaceutical Technology Management, Manufacturing, Supply Chain and Validation. He has experience with sterile, solid dosage, liquid, cream and ointment products. Beginning in 1977 he held various Quality Control roles as a Bench Chemist, Analytical Development Chemist and as Vice President of Quality Control for King Pharmaceuticals sterile facility in Rochester, Michigan. Since 2001 he has held various executive management positions at Parke-Davis/Warner Lambert, King Pharmaceuticals, Graceway Pharmaceuticals, Actient Pharmaceuticals, Rockward Pharmaceutical Consultants and Lynwood Pharmaceuticals. Within these executive management roles he was directly responsible for implementing and managing all key pharmaceutical quality systems for Quality Assurance, Quality Control and Pharmaceutical Technology. He has 20 years of experience in CMO quality systems that support contract customers, as well as the experience of being a customer of CMO’s. Most recently as Sr. Vice President of Quality Operations at Lynwood Pharmaceuticals he was responsible implementing quality systems and for overseeing the development of ANDA’s for solid and semi solid products. Mr. Rutledge received his Bachelor of Science in Chemistry from Lawrence Technological University, Southfield, Michigan.
Herschel Blessing joined UPM as Vice President of Logistics in 2013. Mr. Blessing oversees distribution and inventory management and brings a wealth of experience in distribution and logistics having previously served as Senior Vice President, Logistics, for Graceway Pharmaceuticals, LLC from 2007 through 2011. His previous background includes serving as Executive Vice President of Logistics at SJ Strategic Investments and as Executive Vice President of Distribution at King Pharmaceuticals. Mr. Blessing has over twenty (20) years of experience in the pharmaceutical industry.
Mr. Mughal has 20 years’ experience in Analytical Chemistry with the bulk of his career being spent in the pharmaceutical industry. He joined UPM in 2006, starting as a Senior Analytical Chemist before moving on to a Group Leader/Scientist role and then as the Manager of Analytical Chemistry, leading a team of analytical chemists to support the R&D group and the manufacturing group for testing of everything from raw materials to final product as well as performing method development, transfer and validations. Prior to joining UPM, Mr. Mughal has held QC/Analytical positions at FMC Corporation and Pharmaceutics International Inc. (PII). Mr. Mughal has a Bachelor of Science Degree (Honors) in Chemistry from University of Nairobi and a Master of Science Degree in Biotechnology from Johns Hopkins University.
Mr. Bowles joined UPM as Vice President and General Counsel in 2013. Prior to joining UPM, Mr. Bowles served as Vice President and Corporate Counsel for Graceway Pharmaceuticals from 2007 through 2012. Mr. Bowles primarily works in the fields of corporate law and mergers and acquisitions. Mr. Bowles has overseen and handled multiple complex transactions and has appeared before the State Department, the United States Food & Drug Administration and the United States Environmental Protection Agency. Mr. Bowles was Associate General Counsel for Asahi’s North America operations from 2002 through 2007. Mr. Bowles received a J.D. from The University of Tennessee College of Law in 1994 and worked in private practice prior to joining Asahi in 2002.